Spirometry, rapid FEV1 decline, and lung cancer among asbestos exposed heavy smokers.
We assessed whether spirometric measurements are associated with the development of accelerated FEV(1) decline and lung cancer among active and previous smokers with a wide range of lung function. Bivariate and multivariate analyses that adjusted for age, intervention arm, smoking status at enrollment and smoking history, years exposed to asbestos, and evidence of asbestosis were used to assess whether baseline FEV(1) and FEV(1)/FVC ratio were associated with accelerated FEV(1) decline and incident lung cancer. The 3,041 participants enrolled from 1985 to 1994 were followed through April 30, 2005. Baseline FEV(1)/FVC ratio<0.7 was significantly associated with an increased risk for rapid lung function decline (OR=1.73; 95% CI 1.31-2.28; p<0.001). Baseline FEV(1)/FVC ratio<0.7 was also significantly associated with an increased risk of developing lung cancer, even when baseline FEV(1) was >80%. Lung cancer risk among participants with baseline airflow obstruction and FEV(1)<60% was 4-fold higher than participants without baseline airflow obstruction and FEV(1)>80% (p<0.001), even among former smokers. These data indicate an FEV(1)/FVC<0.7 among smokers is significantly associated with faster airflow loss, and an increased risk for developing lung cancer, even among those individuals with a normal FEV(1).
Chien
Jason W
JW
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. jchien@fhcrc.org
Au
David H
DH
Barnett
Matt J
MJ
Goodman
Gary E
GE
D000368:Aged; D001194:Asbestos / Q000009:adverse effects*; D004311:Double-Blind Method; D004781:Environmental Exposure / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology*; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*; D013147:Spirometry; D014801:Vitamin A / Q000627:therapeutic use*; D014815:Vitamins / Q000627:therapeutic use; D019207:beta Carotene / Q000627:therapeutic use*
D014815:Vitamins; D019207:beta Carotene; D014801:Vitamin A; D001194:Asbestos